Cadence gets SPA for CPI-226 Phase III

Cadence (San Diego, Calif.) received an SPA from FDA for a Phase III trial of CPI-226 omiganan 1% gel to prevent catheter-related infections. The primary endpoint is reduction of incidence of local ca...